PANVIS Star Pan-Vascular Interventional System
PANVIS Star extends Abrobo’s vascular interventional robotics platform beyond neurointerventional applications to encompass coronary and peripheral vascular procedures. Building on the PANVIS COF® fingertip control interface, this second-generation system enables full-procedure robotic assistance including guidewire navigation, catheter manipulation, and device delivery for stenting.
Product Overview
Where PANVIS-A focuses on diagnostic cerebral angiography, PANVIS Star addresses the broader pan-vascular market including percutaneous coronary intervention (PCI)—one of the most commonly performed interventional procedures globally. The system maintains the radiation-protection benefits of remote operation while adding capabilities required for therapeutic interventions.
A defining milestone for the platform occurred in May 2024, when a team led by Academician Ge Junbo at Fudan University’s Zhongshan Hospital used PANVIS to perform a remote coronary intervention on a patient at Kashgar Second People’s Hospital in Xinjiang—a distance of approximately 5,200 kilometers. This procedure demonstrated the system’s capability for telemedicine applications in regions with limited access to experienced interventionalists.
Key Features
PANVIS Star is a pan-vascular interventional robot by Abrobo, extending COF® fingertip control to coronary, peripheral, and neurovascular procedures, including a demonstrated 5,200 km remote PCI.
Full-Procedure Coverage: Robotic control extends from initial guidewire crossing through balloon inflation and stent deployment, eliminating the need for manual intervention during critical procedure phases
Multi-Vessel Capability: Platform designed for coronary, peripheral, and neurovascular applications with appropriate device compatibility for each territory
Integrated Sterile Consumables: Updated design reduces setup time to under 10 minutes compared to earlier system iterations
Remote Operation Architecture: Enables telemedicine applications connecting expert operators at hub centers with patients at spoke facilities
PANVIS COF® Interface: Second-generation fingertip control system optimized for the distinct manipulation requirements of coronary and peripheral procedures
Technical Specifications
PANVIS Star is a second-generation system by Abrobo, covering PCI, PVI, and NVI with sub-millimeter precision and under-10-minute setup for guidewires, balloons, and stents.
| Parameter | Specification |
|---|---|
| Applicable Procedures | PCI, PVI, NVI |
| Control Mode | Master-slave teleoperation |
| Device Compatibility | Guidewires, balloon catheters, stent delivery systems |
| Positioning Precision | Sub-millimeter |
| Setup Time | <10 minutes |
| Remote Operation | Supported (demonstrated at 5,200 km) |
Clinical Applications
PANVIS Star targets the full spectrum of catheter-based vascular interventions:
Coronary Intervention (PCI): Treatment of coronary artery disease through balloon angioplasty and stent placement. Registration clinical trials for this indication completed in late 2024 across multiple centers including Zhongshan Hospital, Hangzhou Normal University Affiliated Hospital, Linfen Central Hospital, and Chengdu Third People’s Hospital.
Peripheral Intervention (PVI): Treatment of peripheral arterial disease affecting vessels in the legs, kidneys, and other non-coronary territories.
Neurovascular Intervention (NVI): Expansion of PANVIS-A capabilities to include therapeutic procedures such as aneurysm coiling, stent-assisted coiling, and mechanical thrombectomy for stroke.
Clinical investigators have noted that the COF interface preserves the fine motor control patterns experienced interventionalists have developed over years of practice, potentially shortening adoption timelines compared to systems requiring fundamentally different control paradigms.
Regulatory Status
| Region | Status | Date | Notes |
|---|---|---|---|
| China (NMPA) | Pending | - | Registration trials completed Q4 2024 |
| EU (CE Mark) | Not Applied | - | - |
| USA (FDA) | Not Applied | - | - |
PANVIS Star completed coronary intervention registration clinical trials in late 2024. The company has indicated it is actively pursuing NMPA submission, with approval anticipated to follow completion of the regulatory review process. Expansion to additional vascular territories (peripheral, neurovascular therapeutic) will require separate indication-specific approvals.
Frequently Asked Questions
How does PANVIS Star differ from PANVIS-A?
PANVIS-A is approved specifically for diagnostic cerebral angiography. PANVIS Star represents a broader platform covering therapeutic procedures across coronary, peripheral, and neurovascular territories. The key additions include support for balloon and stent delivery systems, enabling full-procedure robotic control rather than diagnostic-only applications.
Can PANVIS Star perform remote surgery?
Yes. The system demonstrated long-distance telemedicine capability in May 2024 when operators at Shanghai’s Zhongshan Hospital performed a coronary intervention on a patient 5,200 kilometers away in Kashgar, Xinjiang. The low-latency remote operation architecture enables expert interventionalists at major medical centers to assist or perform procedures at distant facilities.
When will PANVIS Star receive regulatory approval?
Registration clinical trials for coronary intervention completed in late 2024. NMPA submission is underway, though specific approval timing depends on the regulatory review process. The company follows an “in-use, in-development, in-research” product strategy, with new-generation iterations already progressing through clinical validation.
Browse related categories
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.